Aurora B Inhibitors as Cancer Therapeutics
Molecules · 11.04.2023 · 28 (8) · 3385
DOI: 10.3390/molecules28083385 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 11.04.2023. Verfasst von Antal H Kovacs und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Lakehead University, 955 Oliver Road, Thunder Bay, ON P7B 5E1, Canada. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thunder Bay Regional Health Research Insititute / Lakehead University, Natural Sciences and Engineering Research Council, Natural Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
The Aurora kinases (A, B, and C) are a family of three isoform serine/threonine kinases that regulate mitosis and meiosis. The Chromosomal Passenger Complex (CPC), which contains Aurora B as an enzymatic component, plays a critical role in cell division. Aurora B in the CPC ensures faithful chromosome segregation and promotes the correct biorientation of chromosomes on the mitotic spindle. Aurora B overexpression has been observed in several human cancers and has been associated with a poor prognosis for cancer patients. Targeting Aurora B with inhibitors is a promising therapeutic strategy for cancer treatment. In the past decade, Aurora B inhibitors have been extensively pursued in both academia and industry. This paper presents a comprehensive review of the preclinical and clinical candidates of Aurora B inhibitors as potential anticancer drugs. The recent advances in the field of Aurora B inhibitor development will be highlighted, and the binding interactions between Aurora B and inhibitors based on crystal structures will be presented and discussed to provide insights for the future design of more selective Aurora B inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Lakehead University, 955 Oliver Road, Thunder Bay, ON P7B 5E1, Canada.
- Thunder Bay Regional Health Research Institute, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada.
Förderung
- Thunder Bay Regional Health Research Insititute / Lakehead University
- Natural Sciences and Engineering Research Council
- Natural Sciences and Engineering Research Council of Canada
- Thunder Bay Regional Health Research Institute
- Lakehead University
- Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII)
Zitieren
APA
Kovacs, A. H., Zhao, D., & Hou, J. (2023). Aurora B Inhibitors as Cancer Therapeutics. Molecules, 28(8), 3385. https://doi.org/10.3390/molecules28083385
Vancouver
Kovacs AH, Zhao D, Hou J. Aurora B Inhibitors as Cancer Therapeutics. Molecules. 2023;28(8):3385. doi:10.3390/molecules28083385
BibTeX
@article{Kovacs2023,
author = {Kovacs, Antal H and Zhao, Dong and Hou, Jinqiang},
title = {Aurora B Inhibitors as Cancer Therapeutics},
journal = {Molecules},
year = {2023},
volume = {28},
number = {8},
pages = {3385},
doi = {10.3390/molecules28083385}
}
EUVIMED